Patients with T2DM were treated with metformin (81% men, 92% women), sulfonylurea (9% men, 19% women), DPP4 inhibitors (25% men, 24% women), GLP1-analogues (38% men, 43% women), SGLT2-inhibitors (29% men, 16% women) and insulin (68% men, 46% women). The gene discussed is DPP4; the disease is type 2 diabetes mellitus.